Peter G Maslak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8114411/publications.pdf

Version: 2024-02-01

63	11,016	172207	149479
papers	citations	29 h-index	56 g-index

63	63	63	11999
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 2014, 6, 224ra25.	5.8	2,069
2	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 449-459.	13.9	1,951
3	CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine, 2013, 5, 177ra38.	5.8	1,748
4	Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. New England Journal of Medicine, 1998, 339, 1341-1348.	13.9	1,149
5	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011, 118, 4817-4828.	0.6	1,135
6	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	15.2	365
7	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	9.4	270
8	RefractoryAspergillus pneumonia in patients with acute leukemia. Cancer, 2003, 97, 1025-1032.	2.0	234
9	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. Journal of Clinical Oncology, 2001, 19, 1985-1992.	0.8	198
10	Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2002, 20, 2157-2170.	0.8	157
11	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. Science Translational Medicine, 2013, 5, 176ra33.	5.8	147
12	Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2006, 24, 1575-1581.	0.8	146
13	Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood, 2010, 116, 171-179.	0.6	136
14	Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes. Clinical Cancer Research, 2008, 14, 826-832.	3.2	126
15	Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances, 2018, 2, 224-234.	2.5	124
16	WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2010, 59, 1467-1479.	2.0	108
17	Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 1278-1284.	0.8	100
18	Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells. Clinical Cancer Research, 2007, 13, 4547-4555.	3.2	94

#	Article	IF	Citations
19	Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses. Journal of Clinical Oncology, 2009, 27, 491-497.	0.8	66
20	Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discovery, 2022, 12, 62-73.	7.7	65
21	Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 280-317.	2.3	56
22	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood, 2021, 138, 531-543.	0.6	42
23	Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry, 1994, 17, 84-93.	1.8	38
24	CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibodyâ€“based therapy. Blood, 2008, 111, 3403-3406.	0.6	37
25	Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma. American Journal of Clinical Pathology, 2016, 146, 41-49.	0.4	37
26	Diagnosis and treatment of acute promyelocytic leukemia. Current Oncology Reports, 2007, 9, 337-344.	1.8	36
27	A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer, 2002, 95, 581-587.	2.0	32
28	Grading follicular lymphomas in fine-needle aspiration biopsies. Cancer, 2006, 108, 319-323.	2.0	29
29	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia Research, 2013, 37, 32-36.	0.4	29
30	Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood, 2001, 97, 1929-1936.	0.6	25
31	Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections. Transfusion, 2015, 55, 2001-2009.	0.8	25
32	Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. Blood, 2022, 139, 2758-2769.	0.6	25
33	Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer. American Journal of Clinical Pathology, 2014, 142, 506-512.	0.4	24
34	Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica, 2021, 106, 2086-2094.	1.7	24
35	Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opinion on Pharmacotherapy, 2008, 9, 1981-1986.	0.9	22
36	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 2022, 28, 2030-2037.	3.2	21

#	Article	IF	Citations
37	Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. Leukemia and Lymphoma, 2006, 47, 1260-1264.	0.6	16
38	Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?. Cancer, 2013, 119, 1186-1194.	2.0	16
39	Targeted therapies for the myeloid leukaemias. Expert Opinion on Investigational Drugs, 2000, 9, 1197-1205.	1.9	15
40	Evaluation of peripheral blood mononuclear cell collection by leukapheresis. Transfusion, 2019, 59, 1765-1772.	0.8	15
41	Comparison of manual hematocrit determinations versus automated methods for hematopoietic progenitor cell apheresis products. Transfusion, 2016, 56, 528-532.	0.8	11
42	Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. , 1996, 51, 117-121.		9
43	Comparison of Automated Platelet Counts and Potential Effect on Transfusion Decisions in Cancer Patients. American Journal of Clinical Pathology, 2013, 140, 747-754.	0.4	8
44	Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplantation and Cellular Therapy, 2021, 27, 697.e1-697.e5.	0.6	7
45	Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. Journal of Hematopathology, 2016, 9, 9-18.	0.2	6
46	Acute myeloid leukemia with t(5;18)(q35;q21). Cancer Genetics and Cytogenetics, 2001, 127, 71-73.	1.0	5
47	Therapy of Acute Promyelocytic Leukemia. Advances in Pharmacology, 2004, 51, 35-58.	1.2	4
48	Antibodyâ€“drug conjugates in acute myeloid leukemia. Nature Clinical Practice Oncology, 2006, 3, 238-239.	4.3	2
49	Strategy for Incorporating Molecular and Cytogenetic Markers into Acute Myeloid Leukemia Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 995-1002.	2.3	2
50	Translocation t(11;17) in de novo Myelodysplastic Syndrome Not Associated with Acute Myeloid or Acute Promyelocytic Leukemia. Acta Haematologica, 2013, 129, 48-54.	0.7	2
51	Method comparison study of peripheral blood CD34⁺ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	1
52	A simplified <scp>CD34</scp>+ based preharvest prediction tool for <scp>HPC(A)</scp> collection. Transfusion, 2021, 61, 1525-1532.	0.8	1
53	Potential Clinical Impact of Inaccurate Automated Platelet Counts in the Setting of Severe Thrombocytopenia. Blood, 2012, 120, 3428-3428.	0.6	1
54	Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). Blood, 2012, 120, 3624-3624.	0.6	1

#	Article	IF	Citations
55	Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?. Blood, 2013, 122, 2740-2740.	0.6	1
56	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2482-2482.	0.6	1
57	Clinical applications of molecular monitoring in leukemia. Psychophysiology, 2003, 2, 43-8.	1.1	1
58	CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.. Blood, 2006, 108, 3706-3706.	0.6	0
59	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. Blood, 2011, 118, 1765-1765.	0.6	0
60	Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center. Blood, 2011, 118, 4433-4433.	0.6	0
61	Translocation t(11;17) Is Not Always Associated with Acute Myeloid or Acute Promyelocytic Leukemia. Blood, 2011, 118, 5044-5044.	0.6	0
62	High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 4293-4293.	0.6	0
63	Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant. Blood, 2013, 122, 4647-4647.	0.6	0